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Abstract Ribose 5-phosphate isomerase (RPI) deficiency
is an enzymopathy of the pentose phosphate pathway. It
manifests with progressive leukoencephalopathy and pe-
ripheral neuropathy and belongs, with one sole diagnosed
case, to the rarest human disorders. The single patient was
found compound heterozygous for a RPI frameshift and a
missense (RPIAla61Val) allele. Here, we report that two
patient-derived cell lines differ in RPI enzyme activity,
enzyme concentration, and mRNA expression. Further-
more, we present a transgenic yeast model, which exhibits
metabolite- and enzyme-activity changes that correspond to
the human syndrome and show that the decrease in RPI
activity in patient cells is not fully attributable to the residue
exchange. Taken together, our results demonstrate that RPI
deficiency is caused by the combination of a RPI null allele
with an allele that encodes for a partially active enzyme
which has, in addition, cell-type-dependent expression
deficits. We speculate that a low probability for comparable
traits accounts for the rareness of RPI deficiency.
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Introduction
Mutations in the mammalian genome occur non-directed.
Large-scale surveys in mice reveal spontaneous mutation
frequencies that vary around ∼10−6 per locus and gamete [1].
As a consequence, every viable protein deficiency has a
certain incidence. Some enzymopathies, however, are diag-
nosed less frequently as predicted by the natural mutation
rate. This might indicate that the syndrome is not caused by
homozygosis of classic null (total lack of enzyme activity)
alleles. An example is triose-phosphate isomerase (TPI)
deficiency. Several studies report heterozygous null-allele
frequencies between 0.02 and 0.002 [2, 3]. However, since
the discovery of the disorder in the 1960s, less than 100
patients have been diagnosed worldwide [2, 3]. The rare
incidence of this disease is explained by homozygous
lethality of TPI null alleles. The disease only manifests in
individuals that are homozygous or compound heterozygous
for alleles encoding enzyme specimens that are catalytically
active in principal, but have defects in the formation of the
enzyme’s quaternary structure and stability [4, 5]. In contrast
to mutations resulting in an entire loss of protein activity or
presence (e.g., frameshift mutations) that can occur all along
the coding sequence, such alleles are less frequent because
only a few and specific residue exchanges have such effects.
In TPI deficiency, with the exception of a single Hungarian
family, all cases are homozygous or compound heterozygous
for a missense mutation exchanging glutamic acid 105 with
aspartic acid [3, 6].
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Ribose-5-phosphate isomerase deficiency is a defect of
the pentose phosphate pathway (PPP) and with one single
diagnosed case, the rarest possible disease. The particular
patient was born in 1984 and diagnosed via magnetic
resonance imaging to suffer from a progressive brain white
matter disease (leukoencephalopathy) with peripheral neu-
ropathy [7]. Systematic metabolic profiling identified
elevated levels of arabitol and ribitol in affected brain
regions and body fluids. In a subsequent analysis, these
results lead to the discovery of a defect of the PPP enzyme
ribose 5-phosphate isomerase (RPI) [7, 8]. Sequencing of
the RPI-encoding cDNA identified two heterozygous
mutations, one is a frameshift mutation resulting in a
premature termination codon (c.540delG) inherited from
the patient’s mother and a missense mutation (c.182-C→T)
substituting an alanine for valine at codon 61. By
monitoring ribulose 5-phosphate/xylulose 5-phosphate as
well as ribose 5-phosphate formation in fibroblast extracts,
it was concluded that patient cells are deficient for ribose 5-
phosphate isomerase activity [8]
However, since these reports published in 1999 [7]
and 2004 [8], and despite the knowledge that ribitol and
arabitol levels function as disease biomarkers, no further
RPI patients have been identified. Because of the
theoretical number of randomly occurring RPI null
alleles and the strong phenotype of the patient, one
would predict a higher rate of diagnoses. These
observations questioned a classic enzyme loss as the
genetic basis for RPI deficiency. To gain new insights
into the molecular etiology of this disease, we analyzed
the RPI enzyme and metabolite content as well as RPI
enzyme activity in two patient-derived cell lines and a
transgenic yeast model. Reduction of RPI activity in
yeast caused similar changes in polyol profiles as found
in the patient. However, we detected only a partial
influence of the Ala61Val residue exchange on this
phenotype. Instead, we find a strong and cell-type-
dependent reduction of RPI mRNA expression in patient
cells. These results confirm reduced overall RPI enzyme
activity as the cause for the metabolic defects of RPI
deficiency. However, they propose a compound-
heterozygous combination of two alleles, one encoding
for a null allele and the other for a partially active
enzyme with cell-type-dependent expression deficits, as
the molecular cause for this unique case.
Materials and methods
Plasmid generation
The generation of plasmids p416GPD-RPI (containing
the human Rpi1 coding sequence under control of the
GPD1 promoter and URA3 as marker) and p413GPD-RPI
(with HIS3 as marker) was reported previously [9]. To
generating an RPIAla61Val expression plasmid, the 182C→
T transition was induced by generating two partial PCR
products using primer pairs RPI-fwd-BamHI/RPIAla61Val-
rev and RPIAla61Val-fwd/RPI-rev-XhoI (Table 1). The two
PCR products were gel-purified, combined, and used as
template for a second PCR using the primer pair RPI-fwd-
BamHI/RPI-rev-XhoI. The product was digested with the
restriction endonucleases BamHI/XhoI and ligated into
the equally treated expression vector p413GPD [10]. The
plasmid p413CYC-RPI, designed for low-level expression
of RPI, was generated by isolating the RPI-encoding
BamHI/XhoI fragment from p416GPD-RPI and ligating it
into the BamHI/SalI sites of p413CYC. p413CYC and
p413GPD differ only in the yeast promoter (GPD1, CYC1)
sequence [10]. A plasmid for expression of 6xHIS tagged
Escherichia coli transketolase (pRSET-TKL) was gener-
ated by amplifying the E. coli transketolase B gene from
XL1blue genomic DNA using primer pairs TKL-BamHI-
fwd and TKL-XhoI-rev. The product was treated with
BamHI and XhoI and cloned into the T7 expression vector
pRSET-A (Invitrogen). All generated plasmids were
verified by sequencing.
Table 1 DNA primer sequences
Name Sequence in 5′–3′ direction
RPI-fwd-BamHI GAGGATCCATGTCCAAGG
CCGAGGAG
RPIAla61Val-rev AGGATGAGCTGGCGGACC
TGG AAGGAA
RPIAla61Val-fwd TTCCTTCCAGGTCCGCCA
GCTCATCCT
RPI-rev-XhoI TATCTCGAGTCAACAGAA
AGGCTTCTC
RPI-qPCR1-fwd ATTGTCCATGCTGTGCAGCG
RPI-qPCR1-rev GATCACTGAGGGTCAAGCCA
RPI-qPCR2-fwd AGTGCTGGGAATTGGAAGTG
RPI-qPCR2-rev CCTGGAAGGAAGTGGGAATA
RPI-qPCR3-fwd GCCATCGATGGTGCTGATGAA
RPI-qPCR3-rev TCCCCGAGATTCTTCGAATC
HPRT-qPCR-fwd GGTGGAGATGATCTCTCA
ACTTTAA
HPRT-qPCR-rev AGGAAAGCAAAGTCTGCATTGTT
TKL-BamHI-fwd GAGGATCCGGTCGTGGTTCC
CGAAAAGACCTTGCCAA
TKL-XhoI-rev GTGAATTCTCAGGCACCT
TTCACTCCCA
Underlined sequences indicate PCR-introduced restriction sites
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Yeast strain generation and cultivation
Yeast was cultivated at 30°C in yeast-extract peptone
dextrose (YPD) medium. URA3 plasmids were counter-
selected on synthetic complete media supplemented with
0.15% 5′ fluoroorotic acid (5′FOA, Fluorochem). The
S288c (BY4741) derived Δrki1 yeast strain expressing
human RPI from an URA3 centromeric plasmid (MATa
his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 MET15::yor095c pcen-
URA3-GPD1pr-RPI) was generated and transformed as
described previously [9].
Growth curves of transgenic yeast strains were measured
by diluting overnight cultures of freshly grown yeast strains
in triplicates in 30 ml volume to an optical density (OD)600
of 0.15. Cultures were shaken at 30°C, and cell density was
measured hourly on an Ultrospec 2000 (Amersham Phar-
macia) spectrophotometer.
Immunoblotting and antibodies
Proteins were extracted, separated on 12.5% SDS-PAGE
gels, and transferred to nitrocellulose membranes by using a
semidry electroblotter (PeqLAB) as described in [11].
Primary antibodies directed against human RPI (mouse
polyclonal (ab67080), rabbit monoclonal (ab86123), and
GAPDH rabbit polyclonal (ab36840)) were obtained from
Abcam; design and generation of the α-TPI antibody
(rabbit polyclonal) was reported earlier [12].
Relative quantification of RPI in cell extracts by multiple
reaction monitoring (mass western)
Protein samples from control and patient lymphoblast as
well as fibroblast cell lines were separated by 12.5% SDS-
PAGE, and the region encompassing the mass range from
25 to 40 kDa (PageRuler prestained protein ladder
(Fermentas) was used for size orientation) was excised.
Proteins were extracted and digested with trypsin according
to Kaiser et al. [13]. The peptide mixture was separated
using a Zorbax 300SB-C18 (Agilent) column at a flow rate
of 300 nl/min and analyzed on a QTRAP5500 (AB/Sciex)
triple quadrupole mass spectrometer operating in multiple
reaction monitoring (MRM) mode. Identity and specificity
of peptides was verified by mascot (Matrix science) and
blast (NCBI) database searches using MS/MS spectra
obtained on the QTRAP instrument operating in (ion trap)
enhanced product ion mode. Table 2 lists the MRM
transitions used for protein quantification; more details
about chromatographic separations and MS settings are
given in Supplementary Table 2.
Cell culture
Human fibroblasts obtained from five control subjects without
any known defects in metabolism and from the RPI-deficient
individual were grown as monolayers in 175 cm2 flasks
(Nunc) in Ham F-10 medium. When confluent, the cells
were washed twice with Hank’s balanced salt solution
(HBSS) and detached by adding 2 ml of trypsin. Subse-
quently, the cells were isolated by centrifugation for 6 min at
350×g and stored at −80°C until further preparation. Human
lymphoblasts obtained from five control subjects without any
known defects in metabolism and from the RPI-deficient
individual were cultivated in RPMI 1640 medium. Cells
were isolated by centrifugation of the complete cell solution
for 6 min at 350×g, washed with HBSS, and stored at −80°C
until further preparation.
cDNA synthesis and quantitative PCR
Lymphoblast and fibroblast total RNA was extracted using
RNeasy extraction kit (Qiagen) and transcribed into cDNA
using an 12–18 oligo dT primer and Moloney Murine
Leukemia virus (M-MuLV) reverse transcriptase (NEB)
following the manufacturer’s instructions. Primer pairs for
quantitative analysis of RPI mRNA were designed using
Vector NTI software (Invitrogen) and are given in Table 1.
Real-time PCRs were performed in quadruplicates in
5 µl volume using a 2× SybrGreen master mix (Fermentas)
and processed with the ABI Prism 7900HT sequence
detection system (Applied Biosystems). The thermal cy-
cling conditions were 50°C for 2 min, 95°C for 10 min, and
40 cycles of 95°C for 15 s/60°C for 1 min. Amplification
plot and predicted threshold cycle (Ct) values were
obtained with the Sequence Detection Software (SDS 2.1,
Applied Biosystems). For each primer pair, the data were
normalized to the endogenous reference gene (HPRT1,
Table 1) in the respective cell line.
Protein Peptide m/z Quantified fragment Transition m/z
TPI FFVGGNWK 477.75 2y6 477.75–660.35
TPI VVLAYEPVWAIGTGK 801.95 2y9 801.95–928.53
RPI IVAGYASR 418.73 2y6 418.73–624.31
RPI FGGVVELR 438.75 2y7 438.75–729.43
Table 2 MRM transitions
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Enzyme activity assay for ribose 5-phosphate isomerase
For the measurements of RPI activity, the different yeast
cultures were grown in rich medium (YPD) overnight.
Subsequently, cell cultures were diluted, and cultures of
each strain were grown in parallel to mid-log phase. Cells
were collected by centrifugation, washed, shock-frozen in
liquid nitrogen, and lysed by glass beads in 300 μl HBSS.
Human lymphoblasts and fibroblasts were collected by
centrifugation, washed twice, and resuspended in 1 ml
HBSS and sonicated three times for 10 s. The protein
concentration in the supernatant was determined by the
bicinchoninic acid protein assay kit (Sigma, procedure nr.
TPRO-562). Protein extracts were stored at −80°C.
The activity of RPI was quantified spectroscopically by
adapting a protocol from Novello et al. [14]. Twenty-five
micrograms yeast or 75 µg human protein extract was
dissolved in 2 ml 50 mM Tris buffer (pH 7.5) containing
0.1 mM NADH, 0.1 U ribose 5-phosphate epimerase, 0.1 U
TKL, 33.6 U triose-phosphate isomerase, 5.7 U
glyceraldehyde 3-phosphate dehydrogenase, 2 mM MgCl2,
and 0.1 mM thiamine pyrophosphate. After 30 min of
equilibration, the reaction was started at 37°C by adding
6 µmol ribose 5-phosphate. RPI activity was quantified by
the means of following the oxidation of NADH for 60 min
by measuring the absorption at 340 nm. We determined a
limit of detection at an activity of 0.1 µmol mg protein−1
min−1. Enzymes except TKL were obtained from Sigma
Expression and purification of E. coli transketolase
Plasmid pRSET-TKL was transformed into the E. coli
strain BL21pLysS. Expression of the recombinant protein
was induced in a culture growing exponentially at 37°C by
adding 1 mM isopropyl β-D-thiogalactopyranoside. Protein
extracts were generated by adding lysozyme and sonica-
tion; 6× HIS-tagged transketolase was batch-purified using
Ni-NTA sepharose (Qiagen) following the manufacturer’s
instructions.
Quantitative metabolite measurements
For the measurements of sugar phosphates and polyols,
yeast cultures were grown in rich medium (YPD) overnight.
Subsequently, cell cultures were diluted, and two yeast
cultures of each overnight culture were grown in parallel to
mid-log phase. All steps of the lysate generation were
carried out in a cold room at 4°C.
Sugar phosphates Cells were collected by centrifugation,
washed, shock-frozen in liquid nitrogen, and lysed by glass
beads in 400 µl cold HBSS containing 2% perchloric acid
for immediate denaturation of protein after lysis. Samples
were then stored at −20°C and thawed, and 50 µl internal
standard (10 µM 13C6-glucose-6P) was added to 50 µl of
the lysate. Samples were then neutralized with 1 M
phosphate buffer (pH 11.5) and centrifuged for 5 min at
21,000×g at 4°C. Supernatants were transferred to glass
vials and capped. Calibrators of ribose 5-phosphate (r5p),
xylulose/ribulose 5-phosphate (x5p), glucose 6-phosphate
(g6p), sedoheptulose 7-phosphate (s7p), and 6-phospho
gluconate (6pg) were included in each batch of samples and
were processed as described above. Liquid chromatography
tandem mass spectrometry (LC-MS/MS) analysis for
quantification of sugar phosphates was carried out as
described earlier [15, 16].
Polyols Cells were collected by centrifugation, washed,
shock-frozen in liquid nitrogen, and lysed by glass beads in
400 µl coldmethanol/HBSS (without phenol red) in a 2:1 ratio
for immediate denaturation of protein after lysis. Samples
were then stored at −20°C and thawed, and 20 µl internal
standard (10 µM 13C4-erythritol, 25 µM
13C2-arabitol, and
60 µM 13C6-sorbitol) was added to 80 µl of the lysate.
Samples were then centrifuged for 5 min at 21,000×g at 4°C.
Supernatants were transferred to glass vials and capped.
Calibrators of arabitol, ribitol, xylitol, galactitol, and sorbitol
were included in each batch of samples and were processed
as described above. LC-MS/MS analysis for quantification
of polyols was carried out as described earlier [17].
Results
Cell-type-dependent differences in RPI protein and mRNA
expression levels as well as enzyme activity
We cultivated a patient-derived fibroblast and lymphoblast
cell line to monitor the RPI- enzyme and mRNA content in
comparison to respective control cell lines. As illustrated in
Fig. 1a, via western blotting, we detected reduced RPI
enzyme levels in both patient-derived cell lines. In addition,
we noticed that lymphoblasts had a more intense RPI
staining in general. Testing two different RPI antibodies
(Abcam ab67080 polyclonal directed against full-length
RPI and ab86123 monoclonal directed against an N-
terminal peptide), we failed to detect the truncated version
of RPI encoded by the frameshift allele (predicted MW
21 kDa). This indicates that the truncated RPI form is either
not expressed or rapidly degraded. To obtain further and
quantitative information on the RPI enzyme content, via
MRM, we quantified tryptic peptides specific to RPI
relative to the expression of TPI. Whole-cell protein
extracts of patient and control cells were gel-separated;
proteins of a mass range between 25 and 40 kDa were
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extracted and digested. As illustrated in Fig. 1b (a), we
used two specific RPI and TPI peptides for quantification;
for both, we detected multiple co-eluting transitions on the
QTRAP mass spectrometer. To calculate relative alterations
in RPI abundance, we normalized the peak area of the RPI-
specific MRM transitions to the TPI-specific transitions. In
lymphoblasts, MRM intensities of RPI-specific peptides
showed in average a peak area of 30.77% when compared
to control individuals (Fig. 1b (b)), indicating a 70%
reduction of the RPI protein level. Thus, it can be
concluded that the overall RPI protein levels are strongly
reduced in patient cells. Furthermore, we detected strong
quantitative differences in overall RPI expression between
lymphoblasts and fibroblasts. In the fibroblast extracts, the
RPI concentration was below the LC-MS/MS detection
limit for both control and patient lines.
We continued our investigations by assaying RPI mRNA
expression. We isolated total RNA from lymphoblasts and
fibroblasts and transcribed poly-adenylated mRNA into
cDNA. This cDNA was quality-controlled and used for a
relative quantification of RPI expression via quantitative
real-time PCR (qRT-PCR). We designed and tested three
different qPCR primer pairs. Expression levels were
normalized to human hypoxanthin phosphoribosyl transfer-
ase (HPRT) mRNA via the ΔΔCt method. All qPCR
experiments demonstrated a strong decline of RPI expres-
sion in patient cells (Fig. 1c, a representative qPCR
amplification plot is given in Suppl. Fig. 1). Since one of
Fig. 1 RPI protein, mRNA, and activity levels are reduced, but not
necessarily zero, in patient cell lines. a Proteins were extracted from
patient and control lymphoblast as well as fibroblast cell lines and
analyzed via immunoblotting. RPI protein levels were detected with
an antibody directed against human RPI (ab86123); loading and
quality of lysates were controlled with an antibody directed against
TPI. b Relative quantification of RPI via multiple reaction monitoring.
b (a) Chromatograms illustrate the selective detection of RPI and TPI
specific peptides in tryptic digests of control and patient lymphoblasts
via nano-LC-MS/MS operating in multiple reaction monitoring.
Different colors indicate the different MRM transitions given in
Suppl. Table 1. (b) RPI expression in control and patient lymphoblasts
normalized to triose-phosphate-isomerase (TPI) abundance. Bars are
labeled with the amino acid sequences/fragment ions used for
quantification. c RPI relative mRNA concentration determined via
qRT-PCR. Bars represent the average RPI mRNA abundance in
patient cells detected with three primer pairs relative to the expression
in control lymphoblasts or fibroblasts (control). Error bars indicate
the standard deviation. Ct values are given in the supplementary
material. d Overall RPI enzyme activity (substrate conversion per
time) determined with a spectrophotometric enzyme-coupled RPI
enzyme activity assay. Values indicate overall substrate conversion per
time (µmol mg protein−1min−1); bars show normalized enzyme
activity in respect to the corresponding control cell line. n.d. not
detected (<0.1 µmol mg protein−1min−1)
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the alleles encodes a premature stop codon [8], we had
expected a decline in overall RPI mRNA due to activity of
the nonsense mediated decay [18]. However, all qPCR
experiments indicated a reduction of the RPI mRNA below
the 50% margin. This indicates that both alleles are not
expressed at wild-type levels.
Remarkably, also here, we detected strong differences
between fibroblasts and lymphoblasts. In lymphoblasts, the
RPI mRNA was reduced to an average of 0.42×. Although
above the detection limit (Suppl. Fig. 1), RPI levels were
reduced to 0.01× in patient fibroblasts. These results show
that RPI mRNA expression is affected in patient cells.
Furthermore, they reveal that this effect is strongly
dependent on the cell type.
We continued by measuring RPI enzyme activity in both
cell types quantitatively. For this, we adapted a protocol
from [14], which couples ribose 5-phosphate epimerase,
transketolase, triose-phosphate isomerase, and glyceralde-
hyde 3-phosphate dehydrogenase to determine the RPI
activity via the oxidation of NADH in a classic spectro-
photometer. Applying the enzyme-coupled assay, we could
not detect any significant RPI activity in patient fibroblasts
(Fig. 1d); however, patient lymphoblasts exhibited an
activity of 28% compared to wild-type lymphoblasts. In
agreement with the qPCR experiments, these results
indicate that the RPI patient is not suffering from an entire
loss of RPI activity. At least some cell types express the
RPIAla61Val enzyme and have residual activity.
Generation and validation of a yeast model for human RPI
deficiency
The cell culture experiments did not allow us to distinguish
if the reduction in RPI activity is primarily caused by the
exchange of residue Ala61Val in the coding sequence or by
the reduced expression level. Therefore, we generated a
transgenic yeast model for functional analysis of RPI
deficiency. As described earlier [9], we used a haploid
yeast strain (BY4741) and transformed it with a plasmid
encoding for human RPI under control of a strong (GPD1)
promoter and that contained an URA3 (counter-selectable
with 5′FOA) marker. Via a single gene replacement
approach, we subsequently deleted the yeast RPI ortho-
logue RKI1 in the human RPI expressing transformants.
To test the Δrki1 strain, we transformed it with a HIS3
containing plasmid (p413GPD) and with a corresponding
plasmid encoding human RPI (p413GPD-RPI). Positive
transformants were spotted as 1:5 dilution series on media
with and without 5’ FOA. As illustrated in Fig. 2a, only
yeast containing the RPI plasmid were viable on the
counter-selection media. Thus, complete RPI deficiency is
lethal in yeast. Furthermore, this experiment shows that
human RPI can complement for the growth deficits caused
by the lack of its yeast orthologue.
We continued our investigations by generating two new
RPI expression plasmids. First, via PCR, we introduced the
182C to T transition in the single-copy centromeric vector
Fig. 2 A transgenic yeast model for RPI deficiency. a Plasmid shuffle
assay: human RPI complements for its yeast orthologue Rki1p. A
Δrki1 strain expressing human RPI from an URA3 plasmid was
transformed with either an empty or an RPI-encoding HIS3 plasmid
(p413GPD/p413GPD-RPI). Overnight cultures were spotted as 1:5
dilution series on 5′FOA media, which selects for yeast strains that
have lost the URA3 plasmid. Only transformants of the RPI-encoding
vector survived. b Immunoblot analysis of RPI expression in
transgenic yeast expressing RPI, RPIAla61Val under control of the
strong GPD1 promoter, as well as RPI under control of the weak
CYC1 promoter (CYCpr). Parent strain BY4741 was loaded as control;
lysates were controlled with an α-GAPDH antibody. c Ribose 5-
phosphate isomerase activity in Δrki1 yeast expressing RPI, RPIAla61Val
under control of the GPD1 promoter, and RPI under control of the
CYC1 promoter. Bars illustrate normalized overall substrate conversion
per time; values indicate overall substrate conversion per time (µmol mg
protein−1min−1). d Growth of different RPI expressing yeast strains.
Overnight cultures were diluted to an OD600 of 0.15 and grown in
triplicate YPD batch cultures at 30°C. Increase in biomass was followed
by measuring the OD600 hourly. Error bars indicate the standard
deviation
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p413GPD-RPI, resulting in an RPIAla61Val expression plas-
mid. Second, to generate a low-level expression plasmid, we
exchanged the strong GPD1 promoter with the weak CYC1
promoter. Along with respective controls, these plasmids
were transformed into the Δrki1 strain and counter-selected
on 5′FOA. All transformants were viable, indicating that all
plasmids produced functional enzyme species.
We analyzed the RPI enzyme content in these transgenic
yeast strains via immunoblotting (Fig. 2b). Yeast Rki1p
expressed in the parent strain BY4741 was not detected by
the antibody. Human RPI and RPIAla61Val cDNA were
equally expressed in yeast strains harboring the plasmids
with the strong GPD1 promoter; the CYC-promoter
construct produced a significantly weaker band at the same
size.
We measured enzymatic RPI activity in these strains. As
shown in Fig. 2c, the RPIAla61Val expressing ΔRki strain
exhibited 30% of the wild-type activity; the strain express-
ing RPI under the weak CYC1 promoter exhibited 18%
residual activity. These results show that the missense
mutation leading to the exchange of alanine 61 with valine
reduces the activity of RPI. However, in contrast to the
previous assumption [8], the amino acid exchange per se is
not sufficient to explain a RPI haploinsufficiency.
We tested the growth capacities of the different trans-
genic strains. They were pre-grown in YPD media and
diluted to an identical biomass (measured via OD at a
wavelength of 600 nm, cultures were adjusted to an OD600
of 0.15). Growth of triplicate batch cultures at 30°C was
followed spectroscopically. As illustrated in Fig. 2d, yeast
cells expressing human RPI and RPIAla61Val had no obvious
growth defect compared to wild-type strain. However, the
strain expressing RPI under control of the weak CYC1
promoter grew much slower. These results indicate that the
RPIAla61Val allele, if expressed at high levels, is sufficient to
complement for the loss of yeast Rki1p and to promote cell
growth at a normal rate. In contrast, low-level expression of
the wild-type allele did not sufficiently compensate for the
loss of this essential gene.
Transgenic RPI yeast has a metabolic profile similar to RPI
deficiency
The RPI patient presented with a clear metabolic profile,
which included increased ribitol and arabitol levels, as well
as general differences in his polyol profile [7, 8]. These
measurements led to the discovery of the genetic RPI defect
[8]. However, because of the lack of comparable cases, it
was not possible to exclude secondary (i.e., genetic
background) effects that might have contributed or even
caused this metabolic phenotype. We analyzed the polyol
and sugar-phosphate pool of our transgenic yeast strains via
LC-MS/MS to provide an additional and independent proof
that reduced RPI activity is causal for the metabolic defects
of RPI deficiency.
As illustrated in Fig. 3, yeast expressing RPIAla61Val and
RPI under control of the weak promoter exhibited differ-
ences in the cellular metabolite concentrations relative to
yeast expressing wild-type RPI (all measured metabolite
concentrations are given as Supplementary material Table 2).
Analyzing sugar-phosphate intermediates of the PPP, we
detected a clear decrease in ribose-5P and sedoheptulose-7P
concentration (Fig. 3a). The expression of the altered RPI
forms, however, had major influence on the cellular polyol
pool. Polyols are sugar alcohols that can be synthesized from
sugar-phosphates and were found accumulated in patient
samples [8]. All addressed polyols (ribitol, arabitol, xylitol,
galactitol, and sorbitol) were strongly elevated in the yeast
strain expressing RPI under the weak promoter (Fig. 3b).
Remarkably, the most significant metabolic changes were
observed for ribitol, arabitol, and xylitol, which were
increased to 300% and more. These metabolites are highly
elevated in urine, plasma, and CSF of the RPI deficiency
patient [8]. Therefore, these results show that the increase in
polyol metabolites in the patient is indeed attributed to the
reduced RPI activity. Furthermore, they indicate that the RPI
expression level is very critical for the metabolic phenotype
since low-level RPI expression provoked a stronger meta-
bolic phenotype as RPIAla61Val residue exchange.
Fig. 3 Metabolic profile of
transgenic RPI yeast. a Sugar
phosphate and b polyole profile
of wild-type (BY4741) yeast, as
well as RPI expressing Δrki
strains determined via LC-MS/
MS. Given is the concentration
of the indicated metabolites
normalized to the wild-type RPI
expressing strain. Error bars
indicate the standard deviation
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Discussion
Here, we describe a detailed molecular analysis of RPI
deficiency, which is to date, to our knowledge, the rarest
human disease. RPI is an enzyme of the PPP and an
important player of cellular carbohydrate metabolism,
where it interconverts ribose-5-phosphate and ribulose-5-
phosphate [14].
In humans, three enzyme defects of the PPP are associated
with clinical symptoms. Glucose-6-phosphate dehydrogenase
deficiency is the most common human enzyme defect and
present in more than 400 million people worldwide [19].
Transaldolase deficiency, the second defect, was first
described in 2001 [20] and has meanwhile been diagnosed
in unrelated patients of Turkish, Arabian, Pakistani, and
Polish origin [21, 22]. RPI deficiency is the third defect and
appears to be very rare. At the time of the discovery of the
enzyme defect [8], a loss of RPI enzyme activity was assumed
to be the molecular cause of the patient’s molecular and
pathologic phenotype. These conclusions were supported by
LC-MS/MS assays performed on patient’s fibroblast extracts,
which pointed to a deficiency of ribulose-5-phosphate to
ribose-5 phosphate interconversion. A classic loss of enzyme
activity, however, which is caused by multiple types of
mutations that can occur everywhere in the RPI-encoding
sequences (e.g., nucleotide insertions/deletions that result in a
frame shift), would predict some occurrence of RPI cases.
However, in the last 10 years, no further patients have been
reported nor were there any identified in our clinical routine
screening. These observations lead us to considering a more
complex basis of RPI deficiency.
We analyzed two cell lines derived from the patient,
lymphoblasts and fibroblasts. Semi-quantitative western
blotting identified a decline in RPI concentration in both cell
types, and we failed to detect the truncated form encoded by
the frameshift allele. These results were confirmed by
quantitative mass spectrometry, which demonstrated a decline
in RPI level to around 30% of the wild-type level in
lymphoblasts. Furthermore, qPCR experiments demonstrated
that overall RPI mRNA expression was strongly reduced in
patient cells. Surprisingly, we detected huge differences
between the two studied cell lines. Whereas RPI mRNA
levels were reduced to around 40% in lymphoblasts, patient
fibroblasts had only about 1% of RPI mRNA compared to
control fibroblasts. These results are consistent with the
subsequent enzymatic assays that reported a residual RPI
activity of about 30% in lymphoblasts, but an activity below
the assay’s detection limit in fibroblasts. Regarding these
values, it remains possible that different fibroblast cell lines
may vary in RPI enzyme content and activity. However, in a
test experiment, four different control fibroblast lines showed
RPI activities of similar range (5.8/7.3/9.1 and 12.3 nmol µg
protein−1min−1).
Obviously, the allele encoding mutant RPIAla61Val has
two defects. One causes decline in the specific enzyme
activity, and the other results in a cell-type-dependent
decrease in RPI mRNA expression. Future investigations
are needed to clarify the mechanism underlying the mRNA
expression defect. We noticed that the C→T transition is
located in the first codon of exon 3. Therefore, because it is
close to the splice acceptor site, this mutation could affect
the maturation of RPI mRNA. Another possibility is that
this mutation destroys or generates a binding site for a yet
unknown regulatory molecule.
On the organismic level, cell-type dependence of the RPI
defect could serve to explain a major feature of RPI
deficiency. Although the PPP is ubiquitously active, the
RPI patient has a neuronal phenotype. It is possible that the
CNS contains more or a higher percentage of cells
exhibiting the RPI expression defect. However, due to the
lack of biopsy material, it was at present not possible to
address this issue in experiment.
We used a yeast model to compare the effects of the amino
acid exchange and reduced expression level of a wild-type
allele on enzyme activity and metabolic consequences.
RPIAla61Val expressing yeast had about 30% overall enzyme
activity when compared to the isogenic, wild-type RPI
expressing yeast strain. This residual activity was sufficient
to complement for the growth defects of the ΔRki1 strain
and comparable to the enzyme activity detected in patient’s
lymphoblasts. These results reveal that the extremely low
RPI activity in patient’s fibroblast is in large parts attribut-
able to the low expression level of the RPI allele.
Lastly, we report the sugar-phospate and polyol profile
of the RPI-deficient yeast strain. Beside concentration
changes in PPP intermediate sugar phosphates, the yeast
strains strongly accumulated the polyols ribitol, arabitol,
and xylitol. These metabolites were strongly elevated in
body fluids of the patient as well [8]. This result confirms
that polyols are suitable biomarkers for RPI deficiency, a
fact that might facilitate the diagnosis of further cases of
RPI deficiency.
In summary, we provide evidence that defects in RPI
expression are crucial for the phenotype of RPI deficiency.
The expression deficit is dependent on the cell type and
affects an allele which encodes for a partially active RPI
enzyme. The unique patient is compound heterozygous for
this allele and an RPI null allele, which encodes for a
truncated RPI enzyme that was, in addition, not expressed
in patient cell lines. The facts that no individual homozy-
gous for RPI null alleles has been detected, and the RKI1
knock-out is lethal for yeast, allows speculation that cases
with a complete lack of RPI activity are not viable.
Consequently, RPI deficiency is penetrating rarer as the
natural occurrence of null alleles. This fact, however, does
not exclude the possibility that other genetic factors, cell-
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type-dependent modifiers for instance, are contributing to
the rare occurrence of RPI deficiency. It is currently not
certain if similar compound heterozygosities are indeed
compatible with life in other genetic backgrounds.
At present, only a few genes causative for exceptionally
rare genetic disorders are described. This is partly due to
the fact that classic cloning and mapping techniques require
multiple affected (and preferentially unrelated) individuals
for identification of the disease causing gene. However, this
picture may change rapidly because next-generation se-
quencing technologies facilitate the in-depth analyses of
individual human genomes. RPI deficiency may therefore
become part of a larger number of monogenic diseases that
penetrate exceptionally seldom because of a complex
molecular etiology.
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